This study investigated the transfection ability and efficiency of liposomes and immunoliposomes for exogenous gene delivery into the brain via the venous system. Four groups of rats underwent tail vein injection with one of the following: liposomes encapsulating pCMV (human cytomegalovirus promoter)-LacZ plasmid 80 µg (low dose) or 300 µg (high dose); general immunoliposomes encapsulating 80 µg transferrin receptor antibodies (OX26)-pCMV-LacZ plasmid; or brainspecific immunoliposomes encapsulating 80 µg OX26-pGFAP (glial fibrillary acidic protein promoter)-LacZ plasmid. A control group received no injected agent. The LacZ mRNA levels (1 h post-injection) and b-galactosidase activity (48 h postinjection) in the brain and peripheral organs were assayed using real-time reverse transcription-polymerase chain reaction and histochemical staining, respectively. Both immunolipo somes delivered exogenous DNA containing the LacZ gene into the brain after venous injection, resulting in extensive LacZ expression in the brain. Furthermore, the brain-specific OX26-pGFAP-LacZ immunoliposome decreased the non-specific expression of LacZ in peripheral organs without affecting transfection efficiency in the brain. Thus, brain-specific immunoliposomes are an efficient and brainspecific targeting vector.
Introduction
Selection of genes, delivery of vectors and regulation of gene expression are three core gene therapy techniques. In order to guarantee the effectiveness of gene therapy, vectors must help to deliver functional genes to every targeted cell. Central nervous system diseases, such as cerebrovascular disease and dementia, are characterized by extensive pathological changes. In order to achieve effective treatment of these diseases by gene therapy, diffuse transfection of the H Zhao, G-L Li, R-Z Wang et al. Transfection efficiency of liposomes and immunoliposomes brain with appropriate genes is required. Thus, both transfection efficiency and the extent of diffuse transfection are critical for successful gene therapy. Due to recent advances, viral vectors are now commonly used to deliver genes into the central nervous system with high transfection efficiency. 1 -3 Large-sized viral vectors are, however, limited in their diffusion. For example, herpes simplex viruses are neurotoxic, 4 retroviruses tend to combine into the host genome 5 and parvovirus vectors such as adeno-associated viruses have low transfection efficiency and are difficult to prepare. 6 These problems have limited the application of viruses to the central nervous system.
Liposomes are non-viral vectors composed of a lipid bilayer that can decrease toxicity and immunogenicity. They can also be delivered in a targeted manner. For example, transferrin receptor antibodies (OX26) can be coupled to the surface of liposomes to form immunoliposomes that target the liposomes to cells containing transferrin receptors. 7 The brain is a vascular-rich organ and abundant transferrin receptors are extensively distributed on the capillaries of endothelial cells. 8 By triggering receptor-mediated endocytosis at the cell membrane, genes of interest can be delivered into the brain. 9 Because transferrin receptors are also widely distributed in peripheral organs, 10,11 brainspecific gene therapy cannot be achieved by using only general immunoliposomes. To solve this problem, brain-specific gene promoters must be added to vectors to achieve specific gene expression in the brain. 12, 13 The present study was designed to compare the transfection efficiency of lowand high-dose liposomes, general immunoliposomes and brain-specific immunoliposomes. The transferrin receptor antibody (OX26) was purchased from Abcam ® (Cambridge, MA, USA). β-Galactosidase was purchased from Sigma Aldrich (St Louis, MO, USA). The LacZ Detection Kit for Tissues was purchased from InvivoGen (San Diego, CA, USA). The Beta-Glo ® assay system for the detection of β-galactosidase activity was purchased from Promega (Madison, WI, USA). The pCMV-LacZ-liposomes (pCMVliposome), OX26-pCMV-LacZ immunoliposomes (OX26-pCMV-IL) and OX26-pGFAP-LacZ immunoliposomes (OX26-pGFAP-IL) were prepared as described previously. 14 
Materials and methods MATERIALS

IN VIVO ADMINISTRATION OF LIPOSOMES AND IMMUNOLIPOSOMES
REAL-TIME RT-PCR FOR LACZ MRNA
At 1 h post-intravenous injection, 30 rats (n = 6 per group) were decapitated. Fresh whole brain and peripheral organs were preserved in liquid nitrogen. LacZ RNA was isolated and reverse transcribed (RT) to cDNA using an RNeasy ® Mini Kit (Qiagen). Real-time polymerase chain reaction (PCR) for LacZ mRNA was performed with Power SYBR ® Green PCR Master Mix (Applied Biosystems, Foster City, CA, USA) on a thermal cycler (ABI 7900HT; Applied Biosystems). The primer sequences for LacZ mRNA amplification were as follows: sense, 5′-TGGGAGGCTCAAAGCAAGAC-3′; and antisense, 5′-TGACGACAAGGGACAGGTGA T-3′. As an internal control, a commercially available primer set for housekeeping gene ACTB which encodes β-actin (Invitrogen, Carlsbad, CA, USA) was used: sense primer sequence, 5′-CATTGCTGACAGGATGCAG AAG-3′; and antisense primer sequence, 5′-GAGCCACCAATCCACACAGAGT-3′.
The thermal cycling programme involved preliminary denaturation at 95°C for 10 min, followed by 40 cycles of denaturation at 95°C for 15 s, annealing and elongation at 60°C for 60 s. The PCR products were separated on 2% agarose gels and detected using UV light. The data were analysed by SDS software, version 2.2 (Applied Biosystems) and relative quantities were calculated by correcting the expression of LacZ gene with that of the housekeeping gene.
b-GALACTOSIDASE ACTIVITY ASSAY
At 48 h post-intravenous injection, 30 rats (n = 6 per group) were decapitated. Their organs were removed, homogenized in lysis buffer containing 0.1 M potassium phosphate buffer (pH 7.8), 1% Triton X-100, 1 mM dithiothreitol and 2 mM ethylenediaminetetra-acetic acid, and centrifuged. The activity of β-galactosidase in the protein supernatant was then measured using the Beta-Glo ® assay system kit, as previously reported. 15 The relative light unit was determined by a fluorimeter and a standard curve was determined using purified β-galactosidase. Using the standard curve, the relative light unit was converted into picograms (pg) and the quantity of βgalactosidase in each organ was indicated as pg β-galactosidase/mg protein. Organs from control rats were assayed using the same method.
HISTOCHEMICAL STAINING FOR b-GALACTOSIDASE
At 48 h post-intravenous injection, 30 rats (n = 6 per group) were sacrificed and perfused transcardially with 0.01 mM phosphate-buffered saline, pH 7.4, followed by 4% paraformaldehyde. Rats were decapitated, and the brain, heart, liver, spleen, kidney and lung were removed. All organs were fixed in 4% paraformaldehyde overnight and then osmotically dehydrated in increasing sucrose solutions. Brain and peripheral organs were embedded in H Zhao, G-L Li, R-Z Wang et al.
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optimal cutting temperature compound (Sakura Finetek USA, Inc., Torrance, CA, USA) and rapidly frozen in liquid nitrogen. Frozen sections, 12 µm thick, were prepared on a cryostat and β-galactosidase histochemistry was performed using the LacZ Detection Kit for Tissues according to the manufacturer's instructions.
STATISTICAL ANALYSIS
Statistical analyses of the data were carried out using the SPSS ® statistical package, version 13.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . All data were presented as mean ± SD. Data were analysed by Student's t-test or the χ 2 -test. A P-value < 0.05 was considered to be statistically significant.
Results
REAL-TIME RT-PCR FOR LACZ MRNA
In the low-dose pCMV-liposome group, no LacZ mRNA was detected in the heart, kidney and lung (Fig. 1) ; however, expression was detected in the brain, liver and spleen with relative quantities of 9.4263 × 10 -6 , 14.317 × 10 -6 and 112.81 × 10 -6 , respectively. In the high-dose pCMV-liposome group, LacZ mRNA was detected in the brain and all peripheral organs except the heart, and the relative value was statistically significantly higher than that in the low-dose group only for the brain (P < 0.05). In the OX26-pCMV-IL group, LacZ mRNA was detected in the brain as well as in all peripheral organs, except the heart. The relative value in the brain was 22.391 × 10 -6 in FIGURE 1: Relative quantities of LacZ mRNA in the brain and peripheral organs were detected using real-time reverse transcription-polymerase chain reaction 1 h after the injection of liposomes encapsulating 80 µg (low dose) or 300 µg (high dose) pCMV-LacZ plasmid, or general immunoliposomes encapsulating 80 µg OX26-pCMV-LacZ (OX26-pCMV-IL). Control rats were not injected with any agent. The relative values of LacZ mRNA in the brain of rats treated with high-dose pCMV-liposomes and OX26-pCMV-IL were significantly higher than in the low-dose group (*P < 0.05). In the liver and spleen, the relative values of LacZ mRNA in the OX26-pCMV-IL group were significantly lower than in the high-dose pCMV-liposome groups ( † P < 0.05) (n = 6 rats per group). OX26, transferrin receptor antibodies; pCMV-LacZ plasmid, a plasmid containing the LacZ gene under control of the human cytomegalovirus promoter (pCMV) the OX26-pCMV-IL group and 19.182 × 10 -6 in the high-dose pCMV-liposome group, which was statistically significantly higher than that observed for the low-dose pCMV-liposome group (9.4263 × 10 -6 ) (P < 0.05). In the liver and spleen, the relative values of LacZ mRNA in the OX26-pCMV-IL group were statistically significantly lower than in the high-dose pCMV-liposome group (P < 0.05). In the control group, the LacZ gene was not detected in any organ evaluated.
b-GALACTOSIDASE ACTIVITY
In the low-dose pCMV-liposome group, βgalactosidase activity was difficult to detect and was recorded as 'undetected' in several of the organs (Table 1 ). In the high-dose pCMVliposome and OX26-pCMV-IL groups, βgalactosidase activity in all organs, except the spleen, was significantly higher than in the low-dose pCMV-liposome group (P < 0.05). In all three groups, β-galactosidase activity was lowest in the heart and lung, and highest in the liver and kidney, with the exception of the low level found in the liver in the low-dose pCMV-liposome group. There was no β-galactosidase activity detected in the brain, heart, liver and lung of the control group (data not shown).
β-Galactosidase activity in the organs of rats in the OX26-pCMV-IL and OX26-pGFAP-IL groups is compared in Fig. 2 . In the brain of rats treated with OX26-pCMV-IL or OX26-pGFAP-IL, β-galactosidase activity was 0.67 and 0.92 pg/mg protein, respectively, but this difference was not statistically significant. β-Galactosidase activity in the peripheral organs of rats treated with OX26-pGFAP-IL was much lower than in those treated with OX26-pCMV-IL. In the liver, spleen and lung, the respective activities were 0.02, 0.9, 0.01 pg/mg protein in rats treated with OX26-pGFAP-IL versus 5.4, 1.5 and 0.76 pg/mg protein with OX26-pCMV-IL (P < 0.05 for these groups). There was no significant difference in β-galactosidase activity in the kidneys between the two groups (2.9 pg/mg protein for OX26-pGFAP-IL versus 4.7 pg/mg protein for OX26-pCMV-IL).
HISTOCHEMICAL STAINING FOR b-GALACTOSIDASE
Staining for β-galactosidase was not H Zhao, G-L Li, R-Z Wang et al. Transfection efficiency of liposomes and immunoliposomes FIGURE 2: Comparison of β-galactosidase activity in the brain and peripheral organs, as assessed by immunohistochemistry, 48 h after injection of general immunoliposomes encapsulating 80 µg OX26-pCMV-LacZ (OX26-pCMV-IL) or brain-specific immunoliposomes encapsulating OX26-pGFAP-LacZ (OX26-pGFAP-IL). In the brain, there was no statistically significant difference in β-galactosidase activity between the OX26-pGFAP-IL and OX26-pCMV-IL groups. In the liver, spleen and lung, the activity in the OX26-pGFAP-IL group was significantly lower compared with the OX26-pCMV-IL group (*P < 0.05). There was no significant difference in the β-galactosidase activity in the kidneys of these two groups (n = 6 rats per group). OX26, transferrin receptor antibodies; pCMV-LacZ, a plasmid containing the LacZ gene under control of the human cytomegalovirus promoter (pCMV); pGFAP-LacZ, a plasmid that contains the LacZ gene under control of the brainspecific promoter glial fibrillary acidic protein promoter (pGFAP) observed when using the low-dose pCMVliposome dose (data not shown). With the high dose pCMV-LacZ liposomes, positive staining was observed in the brain, but there was much greater staining in the liver and spleen (data not shown). In the OX26-pCMV-IL-treated group, similar staining was seen in the brain, spleen, kidney, liver, lung and heart (data not shown). In the OX26-pGFAP-IL-treated group, staining was observed only in the brain, spleen and kidney, with no staining in the liver, lung or heart. Positive staining for β-galactosidase in the brain pallium, the CA1, CA2 and CA3 regions of the hippocampus, the dentatus gyrus and the pyramidal tracts after the injection of OX26-pGFAP-IL is shown in Fig.  3 . Diffuse expression of β-galactosidase in the brain pallium and hippocampus, with no staining in the heart, liver and lung, after the injection of OX26-pGFAP-IL is shown in Fig. 4 . In the kidney there was positive staining for β-galactosidase activity because of endogenous β-galactosidase-like activity and positive staining was also seen in the spleen. 
Discussion
The two greatest challenges of gene therapy are safety and efficiency. 16 Transfection vectors must possess the qualities of selective targeting and high transfection efficiency. Thus, many gene therapy researchers have tried to improve the specificity and efficiency of vectors. From the present study, we have drawn the following conclusions. First, OX26-targeted immuno liposomes delivered exogenous DNA encoding the LacZ gene through the blood-brain barrier to allow induction of LacZ expression in the brain. Secondly, LacZ expression driven by the GFAP promoter was selectively expressed in the rat brain, but not in peripheral tissues such as the liver, heart and lung. Thirdly, immunoliposomes significantly decreased the amount of lipids and DNA required to achieve adequate transfection. Finally, no acute ill effects of liposomes and immunoliposomes on rats were observed 1 h and 48 h post-injection.
Gene expression in organs, such as the heart or lung, is not expected following intravenous administration of low-dose liposomes because these organs have capillaries with continuous endothelial barriers that do not express significant levels of transferrin receptors. 17 Thus, exogenous gene expression does not occur in the heart and lung and this was confirmed in the present study by the undetectable or very low levels of β-galactosidase activity found in these tissues. If the β-galactosidase activity in the brain had been below the threshold for detection, then it might be assumed that low-dose liposomes could not deliver adequate LacZ gene plasmid into the brain. 15 Gene expression in the brain was achieved, however, with the high-dose of pCMVliposomes in the present study, but this also increased non-specific expression in the peripheral organs. This finding was consistent with a previous report 18 that also demonstrated that high-dose liposomes increase non-specific gene expression.
Immunoliposomes can improve targeting and reduce reticuloendothelial cell uptake in plasma. 16 The present study demonstrated that OX26-pCMV-IL could deliver exogenous genes into the brain at a much lower dose (80 µg of plasmid) than pCMV-liposomes (300 µg of plasmid). Many drugs cannot pass from the peripheral veins across the bloodbrain barrier 14 and, therefore, show great limitation in therapy for intracranial diseases, such as brain ischaemia. To overcome this problem, immunoliposomes could be used to encapsulate drugs or genes into their cores and, due to transferrin receptor expression on the blood-brain barrier, 19 could undergo receptor-mediated transcytosis across the blood-brain barrier in vivo, followed by endocytosis into cells within the brain. The phospholipids forming the liposomes then fuse with the intracellular endosomal membrane subsequent to endocytosis and release plasmid DNA or drugs into the target cells. 20 Parenchymal cells in the liver and spleen also express the transferrin receptor 10, 11 and, therefore, as we showed when using OX26-pCMV-IL as the vector, gene expression was not organ-specific and high LacZ expression was also present in peripheral organs. The OX26-pGFAP-IL contains the brain-specific promoter, GFAP, which is only activated in glial cells. 21 By measuring β-galactosidase activity, it was shown in the present study that when the LacZ gene was under the influence of a GFAP promoter, gene expression in the heart, liver and lung was measurably reduced, which suggests that GFAP promoter-mediated gene transcription did not occur in these peripheral organs. Thus, replacing the CMV promoter with a GFAP promoter made brain-specific gene • Received for publication 12 December 2009 • Accepted subject to revision 17 December 2009
• Revised accepted 11 May 2010 Copyright © 2010 Field House Publishing LLP expression possible. 12 Similar findings have been reported when the LacZ gene was under the influence of the opsin promoter. 13 Histochemical staining also demonstrated that OX26-pGFAP-IL was a good carrier to achieve specific gene expression in the brain. From the histochemical staining pattern, it was observed that diffuse expression in the brain was achieved with OX26-pGFAP-IL, with no expression in the heart, liver or lung. Gene therapy for intracranial disease requires specific expression of exogenous genes in the brain, while avoiding nonspecific expression in peripheral organs. This characteristic of immunoliposomes could, therefore, potentially be used in the clinical setting for humans. Due to the presence of endogenous β-galactosidase-like enzyme activity in the kidney, 16 LacZ gene expression was observed in this organ in the present study. The β-galactosidase-like enzyme activity observed in the spleen has not previously been reported in the literature and requires further validation.
Taken together, the findings of the present study indicate that expression of an exogenous gene in a target organ is a function of both receptor specificity of the targeting ligand and tissue specificity of the promoter regulating the expression of the exogenous gene. This study also demonstrated that OX26-pGFAP-IL is a promising candidate for specific and diffuse exogenous gene delivery to the central nervous system when administered through a vein. It represents a potential method for treating intracranial disease by gene therapy.
